Clinical Trials Logo

Clinical Trial Summary

Pertussis (also known as whooping cough) is a highly contagious, vaccine-preventable respiratory tract disease, caused by the bacteria Bordetella pertussis. It can affect people of all ages, however young unimmunised or partially immunised infants are the most vulnerable group with the highest rates of complications and death. Recent surveillance data and an increase in the number of pertussis outbreaks being reported nationally, indicate an increase in the incidence of pertussis disease in South Africa.To date there is no data on the effect of vaccinating HIV-infected pregnant women with pertussis-containing vaccines, although there is no reason to think that vaccinating these women would be harmful for them or their foetus. The knowledge gaps on the immunogenicity, safety and VE of pertussis vaccination of HIV-infected pregnant women should be addressed. Adacel which is a registered and licensed vaccine manufactured by Sanofi Pasteur, will be tested in this study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05264662
Study type Interventional
Source University of Witwatersrand, South Africa
Contact Marta Nunes, PhD
Phone +27119834283
Email marta.nunes@wits-vida.org
Status Not yet recruiting
Phase Phase 4
Start date March 2022
Completion date June 2025

See also
  Status Clinical Trial Phase
Completed NCT02432430 - Comparison of Immunization Quality Improvement Dissemination Study N/A